Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.92% | 91.64% | 6.58% | 5.03% | -4.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.92% | 91.64% | 6.58% | 5.03% | -4.87% |
| Cost of Revenue | 19.08% | 83.12% | 28.24% | -0.31% | -47.03% |
| Gross Profit | -9.69% | 38.97% | -5.80% | 8.04% | 26.00% |
| SG&A Expenses | -9.17% | -14.25% | -13.99% | -7.55% | 1.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.56% | -22.05% | -14.12% | -17.74% | -21.31% |
| Operating Income | 16.52% | 58.71% | 39.56% | 50.54% | 41.00% |
| Income Before Tax | 75.72% | -29.60% | 74.61% | 32.67% | 16.89% |
| Income Tax Expenses | -- | -107.79% | -- | -- | -- |
| Earnings from Continuing Operations | 75.72% | -19.92% | 74.61% | 32.67% | 16.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.72% | -19.92% | 74.61% | 32.67% | 16.89% |
| EBIT | 16.52% | 58.71% | 39.56% | 50.54% | 41.00% |
| EBITDA | 17.38% | 60.95% | 41.58% | 53.83% | 44.20% |
| EPS Basic | 78.28% | -2.05% | 79.30% | 45.42% | 33.27% |
| Normalized Basic EPS | 78.25% | -7.01% | 79.43% | 47.65% | 33.30% |
| EPS Diluted | 78.28% | -2.05% | 79.30% | 45.42% | 33.27% |
| Normalized Diluted EPS | 78.25% | -7.01% | 79.43% | 47.65% | 33.30% |
| Average Basic Shares Outstanding | 11.57% | 17.53% | 22.71% | 23.38% | 24.63% |
| Average Diluted Shares Outstanding | 11.57% | 17.53% | 22.71% | 23.38% | 24.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |